David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results

2017 ASCO Annual Meeting
Tweet this page

David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)

Advertisement

Advertisement



Advertisement